Login
$IBRX
$5.96 -$0.02 (0.33%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Richard Adcock
CEO and President
57 Not stated $12,716,953
David Sachs
CFO
48 Since 2021
5 years
$4,244,543
Regan Lauer
Chief Accounting Officer
56 Since 2021
5 years
$745,313
Patrick Soon-Shiong Also a director
Founder, Global Chief Scientific and Medical Officer
73 Not stated $12,293,255

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
5 of 5
stated in the proxy; 2 not stated
Average tenure
7.7 years
from year joined
CEO also chairs the board
No
Patrick Soon-Shiong
Director Age On board Independent Committees Other public boards 2025 pay Source
Patrick Soon-Shiong
73 2014
12 years
Not stated
Nominating and Corporate Governance · Chair
None stated Not stated
Cheryl L. Cohen
60 2019
7 years
Independent
Audit Nominating and Corporate Governance Special
Celldex Therapeutics $514,192
Barry J. Simon
61 2007
19 years
Not stated None stated None stated Not stated
Wesley Clark
81 2021
5 years
Independent
Nominating and Corporate Governance Related Party Transaction · Chair
Blue Acquisition Corp., Directa Plus S.p.A., MCF Energy Ltd. $470,589
Linda Maxwell
52 2021
5 years
Independent
Audit Compensation · Chair Related Party Transaction
United Therapeutics Corporation $489,192
Christobel Selecky
71 2021
5 years
Independent
Audit Compensation Related Party Transaction
Teleperformance SE $477,281
Bruce Wendel
72 2025
1 year
Independent
Related Party Transaction
None stated $302,740

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Cambridge
beneficially owned approximately 25.0% of our common stock as of April 13, 2026
$47.5 million
2014

Private placement of 25,191,473 shares of Class A common stock at $1.89 per share under the Cambridge Subscription Agreement

With the company Open in proxy
Dr. Soon-Shiong
selected by Cambridge to hold this Board seat
Amount not stated

Cambridge Nominating Agreement giving Cambridge the right to designate one Board nominee, held by Dr. Soon-Shiong

With Cambridge Open in proxy
Nant Capital
affiliated entity under common control of our Founder, Executive Chairman and Global Chief Scientific and Medical Officer
$505.0 million
2024

Convertible promissory note combining Tranche 1 and Tranche 2 December 2023 notes, Term SOFR plus 8.0%, maturing December 31, 2027

With the company Open in proxy
Nant Capital
affiliated entity under common control of our Founder, Executive Chairman and Global Chief Scientific and Medical Officer
$200.0 million
2023

Convertible promissory note at Term SOFR plus 8.0%, due September 11, 2026, later converted into common stock

With the company Open in proxy
Nant Capital
affiliated entity under common control of our Founder, Executive Chairman and Global Chief Scientific and Medical Officer
$30.0 million
2023

Promissory note at Term SOFR plus 8.0%, later extended and converted into common stock

With the company Open in proxy
Nant Capital
$30.0 million
2023

Promissory note with up to three $10.0 million advances at Term SOFR plus 8.0%

With the company Open in proxy
NantWorks, LLC
Our Founder, Executive Chairman and Global Chief Scientific and Medical Officer also founded and has a controlling interest in NantWorks
$2.1 million, $2.6 million and $3.3 million
2023-2025

Amended and restated shared services agreement under which NantWorks provides support services at cost plus allocations

With the company Open in proxy
NantWorks, LLC
Our Founder, Executive Chairman and Global Chief Scientific and Medical Officer also founded and has a controlling interest in NantWorks
$3.6 million, $3.5 million, and $3.4 million
2023-2025

Facility license agreement with NantWorks for the Culver City office, laboratory and cGMP manufacturing facility

With the company Open in proxy
entities controlled by NantWorks and its affiliates or subsidiaries
Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Founder, Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder
$4.6 million, $4.6 million and $4.5 million
2023-2025

Operating leases of certain assets with entities controlled by NantWorks

With the company Open in proxy
Immuno-Oncology Clinic, Inc.
owned by an officer of the company
Amount not stated

Multiple agreements with the Clinic to conduct clinical trials and provide transition services for product candidates

With the company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support